|
March 2, 2006 Categories: New articles Posted by admin
Clinical trials have begun to assess the feasibility, safety, and efficacy of administering progenitor cells to the heart in order to repair or perhaps reverse the effects of myocardial ischemia and injury. In contrast to surgical-based injections, which are often coupled with coronary bypass surgery, catheter-based injections are less invasive and make it possible to evaluate cell products used as sole interventions.
Link
|
|
